SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – Commonalities and differences in portfolio management practice
8 references·0 citing·33 second hop
Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – Commonalities and differences in portfolio management practice (2008)Value-driven project and portfolio manage…Determining the value of drug development candidates and technology platforms (2005)Determining the value of drug…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…A gene to drug venture: Poisson options analysis (2001)A gene to drug venture: Poiss…Real-Options Valuation for a Biotechnology Company (2000)Real-Options Valuation for a …How SmithKline Beecham makes better resource-allocation decisions. (1998)How SmithKline Beecham makes …Managing the drug discovery/development interface (1997)Managing the drug discovery/d…Valuing Risky Projects: Option Pricing Theory and Decision Analysis (1995)Valuing Risky Projects: Optio…Shareholder Value and Investment Strategy Using the General Portfolio Model (1992)Shareholder Value and Investm…Option pricing: A simplified approach (1979)Real Options: Managerial Flexibility and Strategy in Resource Allocation (1996)Real options: managing strategic investment in an uncertain world (1999)Decision Making Under Uncertainty—Real Options to the Rescue? (2002)Application of real options analysis for pharmaceutical R&D project valuation—Empirical results from a survey (2006)Renewable energy policy evaluation using real option model — The case of Taiwan (2010)The price of innovation: new estimates of drug development costs (2003)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Clinical development success rates for investigational drugs (2014)Scientific management at Merck: An interview with CFO Judy Lewent (1994)Resource interdependence and project termination: An analysis in the biopharmaceutical industry (2020)The present and future of project management in pharmaceutical R&D (2020)A resource‐based view of the firm (1984)Firm Resources and Sustained Competitive Advantage (1991)Management Folklore and Management Science - On Portfolio Planning, Escalation Bias, and Such (1996)Firm resources and sustained competitive advantage (2004)Imitation-related performance outcomes in social trading: A configurational approach (2017)The evolution paths of neutral host businesses: Antecedents, strategies, and business models (2021)The Cost of Capital, Corporation Finance and the Theory of Investment (1958)Martingales and arbitrage in multiperiod securities markets (1979)Decisions with Multiple Objectives: Preferences and Value Tradeoffs. (1994)Challenges to the practical implementation of modeling and valuing real options (1998)Justifying Electronic Banking Network Expansion Using Real Options Analysis1 (2000)Managing Information Technology Investment Risk: A Real Options Perspective (2002)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Learning to improve the decision-making process in research (2004)Strategic planning: valuing and managing portfolios of real options (2006)Open innovation: A real option to restore value to the biopharmaceutical R&D (2013)Subsidies for Renewable Energy Facilities under Uncertainty (2015)Measuring third stream activities (2002)The valuation of a NDA using a 6-fold compound option (2003)Resource Allocation Decisions (2007)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,167 cited
  • 1995Valuing Risky Projects: Option Pricing Theory and Decision Analysis536 cited
  • 1997Managing the drug discovery/development interface523 cited
  • 2000Real-Options Valuation for a Biotechnology Company208 cited
  • 1998How SmithKline Beecham makes better resource-allocation decisions.146 cited
  • 2001A gene to drug venture: Poisson options analysis62 cited
  • 1992Shareholder Value and Investment Strategy Using the General Portfolio Model35 cited
  • 2005Determining the value of drug development candidates and technology platforms35 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work